Appendix A - Inclusion and exclusion criteria

Inclusion criteria	
	Patients with documented acute spinal cord injury above Th11
	Patients can be included in the study within 12 weeks after injury
	Patients with expected dexterity to perform self-intermittent catheterization
	Male or female, aged 18 to 80 years old
	Patient weight > 40 kg
	Patient is able and willing to sign informed consent
	Patient is able to complete all study requirements
Exclusion criteria	
	Neurogenic detrusor overactivity with contractions greater than 40 cm H_2O at first visit
	History or evidence of previous urological abnormalities, disease or surgery, except bladder dysfunction after spinal cord injury
	History of haematuria or ongoing haematuria, if the haematuria is determined to be a pathologic condition or is uninvestigated
	Pregnancy, verified by pregnancy test, or females of childbearing potential unwilling to use a reliable form of contraception
	Breastfeeding
	Known allergy to Onabotulinumtoxin A
	Known grave psychiatric disorder
	Use of anti-platelet or anti-coagulant other than low molecular weight heparin (LMWH) or acetylsalicylic acid
	Haemophilia or other clotting disorders that cause bleeding diathesis
	Treatment with antimuscarinic medication within 3 months prior to randomization
	Treatment with botulinum toxin of any serotype within 12 months prior to randomization
	Patient has been immunized for any botulinum toxin serotype
	Patient has any medical condition that may put the patient at increased risk with exposure to botulinum toxin including diagnosed myasthenia gravis, Eaton-Lambert syndrome or amyotrophic lateral sclerosis
	Patient has any condition or situation, which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the patient's participation in the study

Appendix B – Consort 2025 Flow Diagram